Literature DB >> 11847957

Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors.

Scott Bolesta1, Stacy L Haber.   

Abstract

OBJECTIVE: To evaluate the literature regarding the potential of acetaminophen to cause toxicity in adult patients without risk factors, when used chronically in daily doses < or = 4 g. DATA SOURCES: Key tertiary literature was reviewed, along with searches of MEDLINE (1966-July 2001). International Pharmaceutical Abstracts (1970-May 2001), and PREMEDLINE (July Week 5, 2001). Key search terms included acetaminophen, paracetamol, toxic hepatitis, hepatotoxicity, liver dysfunction, overdose, drug toxicity, and poisoning. DATA SYNTHESIS: Most tertiary references state that the maximum daily dose of acetaminophen is 4 g. Patients taking more than this amount, especially those with certain risk factors, are more likely to develop toxicity. However, a few patients may develop toxicity regardless of risk. An evaluation of the literature regarding the toxic potential of acetaminophen when given at doses < or = 4 g/d chronically (> or = 4 d) to adult patients without risk factors was conducted.
CONCLUSIONS: Acetaminophen should be used cautiously on a chronic basis because several case reports show that it may be hepatotoxic at therapeutic doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847957     DOI: 10.1345/aph.1A035

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  13 in total

1.  A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain.

Authors:  Alex W Thomas; Karissa Graham; Frank S Prato; Julia McKay; Patricia Morley Forster; Dwight E Moulin; Sesh Chari
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

Review 2.  Pain management in the cirrhotic patient: the clinical challenge.

Authors:  Natasha Chandok; Kymberly D S Watt
Journal:  Mayo Clin Proc       Date:  2010-03-31       Impact factor: 7.616

3.  Possible hepatotoxicity associated with intravenous acetaminophen in a 36-year-old female patient.

Authors:  Philip J Lee; Mark Shen; Shan Wang; Peter Spiegler; Thomas Caraccio; Jonas P DeMuro; Brian Malone
Journal:  P T       Date:  2015-02

4.  Acetaminophen has limited antipyretic activity in critically ill patients.

Authors:  Rachel S Greenberg; Hegang Chen; Jeffrey D Hasday
Journal:  J Crit Care       Date:  2009-09-24       Impact factor: 3.425

Review 5.  Drug-induced liver injury in older adults.

Authors:  Sarah J Mitchell; Sarah N Hilmer
Journal:  Ther Adv Drug Saf       Date:  2010-12

6.  Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling.

Authors:  Size Li; Yiqun Yu; Xiaolan Bian; Li Yao; Min Li; Yan-Ru Lou; Jing Yuan; Hai-Shu Lin; Lucy Liu; Bing Han; Xiaoqiang Xiang
Journal:  Arch Toxicol       Date:  2021-03-13       Impact factor: 5.153

7.  Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study.

Authors:  Roderick Clark; Judith E Fisher; Ingrid S Sketris; Grace M Johnston
Journal:  BMC Clin Pharmacol       Date:  2012-06-18

8.  Acetaminophen induces apoptosis in rat cortical neurons.

Authors:  Inmaculada Posadas; Pablo Santos; Almudena Blanco; Maríangeles Muñoz-Fernández; Valentín Ceña
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

9.  Age-related changes in the hepatic pharmacology and toxicology of paracetamol.

Authors:  Sarah J Mitchell; Alice E Kane; Sarah N Hilmer
Journal:  Curr Gerontol Geriatr Res       Date:  2011-05-11

10.  Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series.

Authors:  Mònica Sabaté; Luisa Ibáñez; Eulàlia Pérez; Xavier Vidal; Maria Buti; Xavier Xiol; Antoni Mas; Carlos Guarner; Montserrat Forné; Ricard Solà; José Castellote; Joaquim Rigau; Joan-Ramon Laporte
Journal:  BMC Gastroenterol       Date:  2011-07-15       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.